RxDoctor Payments Data

Nestor Flores, MD

Pulmonary Disease · Guayama, PRNPI 1801015060

Payments from drug & device makers

$640in general payments, 2019–2025

Across 27 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$305
  • Johnson & Johnson$157
  • Pfizer$125
  • Chiesi USA, Inc.$20
  • Takeda Pharmaceuticals U.S.A., Inc.$15
  • PBG Puerto Rico LLC$9
  • plus $9 from 1 others

What the payments were for

  • Food & beverage$640100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim18$305
Johnson & Johnson4$157
Pfizer1$125
Chiesi USA, Inc.1$20
Takeda Pharmaceuticals U.S.A., Inc.1$15
PBG Puerto Rico LLC1$9
Pfizer Pharmaceuticals LLC1$9

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$640 in reported general payments places this provider in the 15th percentile of 138 pulmonary disease providers in Puerto Rico.

See all pulmonary disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$3,481
Medicare patients
17
Services billed
65

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Spiriva RespimatTiotropium Bromide803$429,876
Trelegy ElliptaFluticasone/Umeclidin/Vilanter374$249,564
Stiolto RespimatTiotropium Br/Olodaterol Hcl469$231,755
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate537$146,711
Arnuity ElliptaFluticasone Furoate390$84,256
SymbicortBudesonide/Formoterol Fumarate323$78,848
Fluticasone Propionate HfaFluticasone Propionate306$69,763
Breo ElliptaFluticasone/Vilanterol141$58,382
Fluticasone Propionate1,377$23,690
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr38$18,208
Albuterol Sulfate HfaAlbuterol Sulfate342$15,612
Wixela InhubFluticasone Propion/Salmeterol73$15,011
Montelukast Sodium1,866$14,249
Desloratadine603$13,652
Advair HfaFluticasone Propion/Salmeterol32$10,495

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$305$661,6311,272 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 138 pulmonary disease providers in Puerto Rico.

Other pulmonary disease in Guayama

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →